[go: up one dir, main page]

WO2013011062A3 - Antagonistes oscar - Google Patents

Antagonistes oscar Download PDF

Info

Publication number
WO2013011062A3
WO2013011062A3 PCT/EP2012/064109 EP2012064109W WO2013011062A3 WO 2013011062 A3 WO2013011062 A3 WO 2013011062A3 EP 2012064109 W EP2012064109 W EP 2012064109W WO 2013011062 A3 WO2013011062 A3 WO 2013011062A3
Authority
WO
WIPO (PCT)
Prior art keywords
oscar
antibodies against
antagonistic antibodies
antagonistic
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/064109
Other languages
English (en)
Other versions
WO2013011062A2 (fr
Inventor
Li Guo
Svetlana PANINA
Jesper Pass
Louise Hjerrild ZEUTHEN
Louise Maymann NITZE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2013011062A2 publication Critical patent/WO2013011062A2/fr
Publication of WO2013011062A3 publication Critical patent/WO2013011062A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des ligands antagonistes thérapeutiques OSCAR. La présente invention concerne en outre l'utilisation de ces ligands.
PCT/EP2012/064109 2011-07-18 2012-07-18 Antagonistes oscar Ceased WO2013011062A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2011001174 2011-07-18
CNPCT/CN2011/001174 2011-07-18
US201161524426P 2011-08-17 2011-08-17
US61/524,426 2011-08-17
CNPCT/CN2012/076144 2012-05-28
CN2012076144 2012-05-28
US201261662643P 2012-06-21 2012-06-21
US61/662,643 2012-06-21

Publications (2)

Publication Number Publication Date
WO2013011062A2 WO2013011062A2 (fr) 2013-01-24
WO2013011062A3 true WO2013011062A3 (fr) 2013-03-21

Family

ID=46513781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/064109 Ceased WO2013011062A2 (fr) 2011-07-18 2012-07-18 Antagonistes oscar

Country Status (1)

Country Link
WO (1) WO2013011062A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123642A1 (fr) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Méthodes et utilisations du récepteur associé à l'ostéoclaste (oscar) pour la prévention et le traitement de l'arthrose
KR102316299B1 (ko) * 2018-11-30 2021-10-22 이화여자대학교 산학협력단 오스카 단백질-콜라겐 상호작용 저해제 스크리닝용 조성물, 이를 포함하는 키트, 및 이를 이용한 스크리닝 방법
WO2022119076A1 (fr) * 2020-12-03 2022-06-09 이뮤노포지 주식회사 Protéine de fusion comprenant un agoniste du récepteur glp-1 et un anticorps anti-oscar, et utilisation associée
CN119424633B (zh) * 2024-11-07 2025-07-25 浙江赛尔共银生物科技有限公司 一种包含间充质干细胞治疗退行性关节炎的组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053368A1 (fr) * 2007-10-22 2009-04-30 Merck Serono S.A. Ifn-bêta unique fusionné à un fragment fc d'igg muté
WO2010040998A1 (fr) * 2008-10-06 2010-04-15 Cambridge Enterprise Llimited Modulation de l'activité et de la différenciation de cellules exprimant le récepteur associé à l'ostéoclaste

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (fr) 2003-10-28 2005-05-06 Novo Nordisk A/S Peptides fixant la laminine-5 gamma-2, compositions associees et leurs applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053368A1 (fr) * 2007-10-22 2009-04-30 Merck Serono S.A. Ifn-bêta unique fusionné à un fragment fc d'igg muté
WO2010040998A1 (fr) * 2008-10-06 2010-04-15 Cambridge Enterprise Llimited Modulation de l'activité et de la différenciation de cellules exprimant le récepteur associé à l'ostéoclaste

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. MERCK ET AL.: "Fc-receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses.", BLOOD, vol. 105, no. 9, 1 May 2005 (2005-05-01), USA, pages 3623 - 3632, XP002681827 *
U. BRAND ET AL.: "Influence of extracellular matrix proteins on the development of cultured human dendritic cells.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 5, 1 May 1998 (1998-05-01), Germany, pages 1673 - 1680, XP002403016 *

Also Published As

Publication number Publication date
WO2013011062A2 (fr) 2013-01-24

Similar Documents

Publication Publication Date Title
IL323371A (en) Broadly neutralizing antibodies against the AIDS virus
IL269322B (en) Methylphenidate-medications, processes for their preparation and use
EP3378850B8 (fr) Procédés pour la préparation de (s)-l-(3-éthoxy-4-méthoxyphényl)-2- méthanesulfonyléthylamine
GB2501687B (en) Improvements relating to the transmission of energy
EP2917462B8 (fr) Isolation de puits
IL228001B (en) Antibodies to 70cd
IL230719A0 (en) highly galactosylated antibodies
IL229410A0 (en) Metabolized pyridopyrazines as novel cyk inhibitors
WO2013011062A3 (fr) Antagonistes oscar
ZA201302639B (en) Antibodies for the treatment of hiv
WO2012004073A3 (fr) UTILISATION DE β-ISOPHORONE COMME SOLVANT
PT2702045T (pt) Método inovador para a preparação de etravirina
EP2613831A4 (fr) Dispositif de pression positive des voies respiratoires continues nasales pour réduire l'effort de respiration
HK40115212A (zh) 广泛中和性抗hiv抗体
SG11201406582XA (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the
AU2012900977A0 (en) Improvements to the manufacture of biochar-coke
UA72478U (ru) Применение полентара как средства фригопротекторного действия
AU2011900644A0 (en) Therapeutic Uses of SLIRP
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
HK1191193B (en) Backpack
AU2012901379A0 (en) Antibodies to HtrA3
EP3090742A4 (fr) Utilisation de composés obtenus à partir d'extraits d'arrabidaea brachypoda comme anti-ulcérogène
AU2012900227A0 (en) Compositions of nimorazole
AU2012901311A0 (en) Provision of entertainment
AU2012901994A0 (en) Spred easy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12735312

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12735312

Country of ref document: EP

Kind code of ref document: A2